Announcements Trials

Browse Landscape

Phase

Phase 1 4 Phase 1/2 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 199 Rectal Neoplasms 106 Colonic Neoplasms 78 Stomach Neoplasms 64 Pancreatic Neoplasms 56 Neoplasm Metastasis 50 Esophageal Neoplasms 34 Neoplasms 25 Lymphoma 24 Leukemia 24 Adenocarcinoma Of Esophagus 22 Burkitt Lymphoma 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Carcinoma, Hepatocellular 16 Cholangiocarcinoma 15 Adenocarcinoma 15 Biliary Tract Neoplasms 12 Gallbladder Neoplasms 9 Bile Duct Neoplasms 8 Lymphoma, Mantle-Cell 7 Colorectal Cancer Metastatic 7 Osteosarcoma 6 Esophageal Squamous Cell Carcinoma 6 Lymphoma, Non-Hodgkin 5 Lymphoma, Large B-Cell, Diffuse 5 Liver Neoplasms 5 Dendritic Cell Sarcoma, Interdigitating 5 Breast Neoplasms 5 Sarcoma 4 Peritoneal Neoplasms 4

Interventions

Carboplatin 79 pembrolizumab 64 Paclitaxel 64 Cyclophosphamide 47 Capecitabine 34 Doxorubicin 31 Taxes 28 130-nm albumin-bound paclitaxel 28 Albumin-Bound Paclitaxel 27 Gemcitabine 20 atezolizumab 18 Epirubicin 18 Cisplatin 18 Bevacizumab 18 olaparib 17 sacituzumab govitecan 15 Docetaxel 15 eribulin 14 toripalimab 13 durvalumab 13 camrelizumab 13 Drug Therapy 12 apatinib 9 Trastuzumab 9 Radiotherapy 9 Specimen Handling 8 Magnetic Resonance Spectroscopy 8 Biopsy 8 tislelizumab 7 talazoparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Triple Negative Breast Neoplasms × Leucovorin × Clear all

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡